2C-B

2C-B
	2C-B structure
	3D representation of a 2C-B molecule
Clinical data
Other names	4-Bromo-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-bromophenethylamine; Nexus; Venus; Bromo; Bees; Erox; Synergy; Performax; Toonies
Routes of; administration	By mouth, insufflation, rectal
Drug class	Serotonergic psychedelic; Hallucinogen; Serotonin 5-HT2A receptor agonist
ATC code	None;
Legal status
Legal status	AU: S9 (Prohibited substance); BR: Class F2 (Prohibited psychotropics); CA: Schedule III; DE: Anlage I (Authorized scientific use only); UK: Class A; US: Schedule I; UN: Psychotropic Schedule II;
Pharmacokinetic data
Metabolism	Liver (MAO and CYP450)
Metabolites	BDMPE, BDMPAA, BDMBA, and others
Onset of action	Oral: 20–90 min
Elimination half-life	1.2–2.5 hours
Duration of action	Oral: 2–8 hours
Excretion	Urine
Identifiers
	IUPAC name 2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine;
CAS Number	66142-81-2;
PubChem CID	98527;
DrugBank	DB01537;
ChemSpider	88978;
UNII	V77772N32H;
KEGG	C22775;
ChEBI	CHEBI:189669;
ChEMBL	ChEMBL292821;
CompTox Dashboard (EPA)	DTXSID10216332 ;
ECHA InfoCard	100.164.088
Chemical and physical data
Formula	C10H14BrNO2
Molar mass	260.131 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(CCN)c(OC)cc1Br;
	InChI InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3; Key:YMHOBZXQZVXHBM-UHFFFAOYSA-N;

2C-B, also known as 4-bromo-2,5-dimethoxyphenethylamine or by the slang name Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug.^[2]^[1]^[6] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy.

To date, there is limited scientific information regarding the drug's pharmacokinetics and pharmacological effects in humans. The existing studies primarily classify 2C-B as a stimulant and hallucinogen, and less commonly an entactogen.^[7]

2C-B is also known by a number of slang names and appears on the illicit market in multiple forms:^[8]^[9] as a powder, in capsules or pills. For recreational use, the substance is generally consumed orally or nasally.

^ ^a ^b ^c ^d ^e Nugteren-van Lonkhuyzen JJ, van Riel AJ, Brunt TM, Hondebrink L (December 2015). "Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans". Drug Alcohol Depend. 157: 18–27. doi:10.1016/j.drugalcdep.2015.10.011. PMID 26530501.
^ ^a ^b ^c ^d ^e Cole MD, Lea C, Oxley N (2002). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature". Sci Justice. 42 (4): 223–224. doi:10.1016/S1355-0306(02)71832-7. PMID 12632938.
^ Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura M, Pujadas M, et al. (2018). "Acute Pharmacological Effects of 2C-B in Humans: An Observational Study". Frontiers in Pharmacology. 9: 206. doi:10.3389/fphar.2018.00206. PMC 5859368. PMID 29593537.
^ Thomann J, Rudin D, Kraus S, Arikci D, Holze F, Liechti ME, et al. (2025). "LC–MS/MS-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolites in human plasma". Drug Metabolism and Disposition: 100086. doi:10.1016/j.dmd.2025.100086.
^ ^a ^b Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJ (April 2020). "Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review". Ther Drug Monit. 42 (2): 271–281. doi:10.1097/FTD.0000000000000725. PMID 32022784.
^ Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, et al. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". Journal of Psychopharmacology. 26 (7): 1026–1035. doi:10.1177/0269881111431752. PMID 22234927. S2CID 35535891.
^ González D, Torrens M, Farré M (2015-10-12). "Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions". BioMed Research International. 2015: 643878. doi:10.1155/2015/643878. PMC 4620274. PMID 26543863.
^ "2C-B Street Names" (PDF). February 1, 2011. Archived from the original (PDF) on October 16, 2012. Retrieved 2012-09-28.
^ Westhoff B (2019). Fentanyl, Inc. New York: Atlantic Monthly Press. p. 62. ISBN 978-1-0941-6390-1. OCLC 1136538402.

[Nugteren-vanLonkhuyzenvanRielBrunt2015-1] Nugteren-van Lonkhuyzen JJ, van Riel AJ, Brunt TM, Hondebrink L (December 2015). "Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans". Drug Alcohol Depend. 157: 18–27. doi:10.1016/j.drugalcdep.2015.10.011. PMID 26530501.

[ColeLeaOxley2002-2] Cole MD, Lea C, Oxley N (2002). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature". Sci Justice. 42 (4): 223–224. doi:10.1016/S1355-0306(02)71832-7. PMID 12632938.

[PapaseitFarréPérez-Mañá2018-3] Papaseit E, Farré M, Pérez-Mañá C, Torrens M, Ventura M, Pujadas M, et al. (2018). "Acute Pharmacological Effects of 2C-B in Humans: An Observational Study". Frontiers in Pharmacology. 9: 206. doi:10.3389/fphar.2018.00206. PMC 5859368. PMID 29593537.

[ThomannRudinKraus2025-4] Thomann J, Rudin D, Kraus S, Arikci D, Holze F, Liechti ME, et al. (2025). "LC–MS/MS-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolites in human plasma". Drug Metabolism and Disposition: 100086. doi:10.1016/j.dmd.2025.100086.

[InanBruntContrucci2020-5] Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJ (April 2020). "Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review". Ther Drug Monit. 42 (2): 271–281. doi:10.1097/FTD.0000000000000725. PMID 32022784.

[6] Caudevilla-Gálligo F, Riba J, Ventura M, González D, Farré M, Barbanoj MJ, et al. (July 2012). "4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects". Journal of Psychopharmacology. 26 (7): 1026–1035. doi:10.1177/0269881111431752. PMID 22234927. S2CID 35535891.

[GonzálezTorrensFarré2015-7] González D, Torrens M, Farré M (2015-10-12). "Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions". BioMed Research International. 2015: 643878. doi:10.1155/2015/643878. PMC 4620274. PMID 26543863.

[DEA_-_Evaluation_Section-8] "2C-B Street Names" (PDF). February 1, 2011. Archived from the original (PDF) on October 16, 2012. Retrieved 2012-09-28.

[9] Westhoff B (2019). Fentanyl, Inc. New York: Atlantic Monthly Press. p. 62. ISBN 978-1-0941-6390-1. OCLC 1136538402.

[1]

[5]

[2]

[3]

[4]

[6]

[7]

[8]

[9]